Related Experiment Video
Updated: May 18, 2026

How to Study Placebo Responses in Motion Sickness with a Rotation Chair Paradigm in Healthy Participants
Published on: December 14, 2014
Placebo? no thanks, it might be bad for me!
Silvio Garattini1, Vittorio Bertelé, Rita Banzi
1Istituto di Ricerche Farmacologiche Mario Negri, Via Giuseppe La Masa 19, 20156 Milan, Italy. silvio.garattini@marionegri.it
Objective:
To assess the potential damage to patients from the inappropriate use of placebo.
Methods:
Pivotal clinical trials of new drugs were evaluated for the treatment of multiple sclerosis following effective treatment with beta interferons and glatiramer acetate. The differences in the relapse rate between the experimental arms of the trials with interferons and glatiramer and the placebo groups were calculated.
Results:
In ten pivotal trials, 2,752 patients were given placebo instead of the best proven treatments. The annualized relapse rate was reported for 2,405 of these patients. Patients receiving placebo suffered 630 more relapses than those treated with interferons or glatiramer.
Conclusions:
The inappropriate use of placebo in clinical trials unduly harms patients. The use of standard active comparators would preserve patients' rights and better define the respective clinical value of new medicines.
Related Concept Videos
The Placebo Effect
Blind Procedures
Blinding
Classical Conditioning in Daily Life
John B. Watson and Rosalie Rayner famously demonstrated the development of fear through classical conditioning in their experiment with Little Albert. They paired the...
Bioavailability Study Design: Healthy Subjects Versus Patients
Skeletal Muscle Relaxants: Adverse Effects
Unlike...

